Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Secondary to Toxoplasmic Retinochoroiditis: A Case Series

Abstract

Intravitreal bevacizumab seems to be an effective treatment for the long-term control of juxta/subfoveal CNV secondary to toxoplasmic retinochoroiditis. Further trials are mandatory to validate the data of our case series.